FDA Safety Request Delays Novartis Phase III Program For MS Agent FTY720
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis is delaying the start of Phase III clinical trials for its oral multiple sclerosis treatment FTY720 until the fourth quarter following a request for a safety analysis from FDA
You may also be interested in...
Teva Jockeys For Advantage In Wake Of Tysabri Withdrawal, Avonex Warning
Tysabri withdrawal effects: GlaxoSmithKline, Antisense Therapeutics halt MS drug Phase II trials, citing identical mechanism of action. Teva, Serono, Schering jockey for advantage over Biogen Idec following additional reports of PML in Tysabri recipients, addition of Avonex liver warning
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product